111 Capital Buys 4,958 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• 111 Capital increased its stake in Thermo Fisher Scientific Inc. by 150.1%, purchasing an additional 4,958 shares, bringing its total holdings to 8,261 shares worth approximately $3.35 million.
• Institutional investors collectively own 89.23% of Thermo Fisher Scientific, with several hedge funds significantly increasing their positions in recent quarters.
• Thermo Fisher Scientific has announced a quarterly dividend of $0.43 per share, set to be paid on October 15th, representing an annualized yield of 0.3%.

111 Capital lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 150.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 8,261 shares of the medical research company's stock after purchasing an additional 4,958 shares during the quarter. 111 Capital's holdings in Thermo Fisher Scientific were worth $3,350,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Mondrian Investment Partners LTD increased its stake in Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after acquiring an additional 127,357 shares during the last quarter. Caledonia Investments PLC increased its stake in Thermo Fisher Scientific by 11.5% in the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company's stock worth $45,299,000 after acquiring an additional 11,500 shares during the last quarter. Foresight Group Ltd Liability Partnership increased its position in shares of Thermo Fisher Scientific by 3,242.7% during the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company's stock valued at $29,113,000 after purchasing an additional 56,747 shares during the last quarter. Advisors Capital Management LLC lifted its position in Thermo Fisher Scientific by 6.7% in the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock worth $63,201,000 after buying an additional 7,967 shares during the last quarter. Finally, New England Research & Management Inc. boosted its stake in Thermo Fisher Scientific by 28.6% in the second quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company's stock worth $1,033,000 after buying an additional 567 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on TMO. William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating for the company. HSBC reaffirmed a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research note on Friday, July 11th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus target price of $585.37.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $543.88 on Friday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market cap of $205.37 billion, a PE ratio of 31.46, a P/E/G ratio of 2.85 and a beta of 0.77. The business has a 50 day moving average of $482.58 and a 200 day moving average of $447.76. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the company earned $5.37 earnings per share. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.